Company Description
Conexeu Sciences Inc. develops collagen-based regenerative tissue scaffold products for applications in medical aesthetics and tissue repair.
The company provides patented collagen-based scaffold products, including a collagen extracellular matrix (ECM) scaffold platform for use in medical aesthetics, wound care, tissue repair, facial rejuvenation, and large-volume body contouring such as face, breast, and butt volume restoration.
Its CXU collagen gel is an investigational product targeting therapeutic and aesthetic indications, supporting tissue regeneration and aiming to minimize inflammation or fibrosis.
The company’s solutions are supported by preclinical and peer-reviewed data and are positioned as alternatives to conventional fillers or implants, with products currently investigational and pending regulatory clearance for certain applications.
The company serves clients in the beauty, aesthetics, regenerative medicine, and medical sectors, including clinicians and professionals involved in facial rejuvenation, body contouring, wound care, and tissue repair.
The company was founded in 2022 and is based in Reno, Nevada.
| Country | United States |
| Founded | 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Miles Harrison |
Contact Details
Address: 50 West Liberty Street, Suite 880 Reno, Nevada 89501 United States | |
| Phone | (604) 315-4722 |
| Website | conexeu.com |
Stock Details
| Ticker Symbol | CNXU |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | November - October |
| Reporting Currency | USD |
| CIK Code | 2066836 |
| CUSIP Number | 20715F100 |
| ISIN Number | US20715F1003 |
| SIC Code | 3842 |
Key Executives
| Name | Position |
|---|---|
| Miles D. Harrison | President, Chief Executive Officer and Director |
| David R. Bogart | Founder, Chief Commercial Officer and Director |
| Dr. Claudia Chavez-Munoz M.D., Ph.D. | Founder and Chief Scientific Officer |
| Stephen D. Inouye | Chief Financial Officer, Corporate Secretary and Treasurer |
| Dr. Brian K. Pilcher Ph.D. | Chief Medical Officer |
| Sonia Thomas M.B.A. | Head of Strategy and Transformation |
| Jean-Romain Falconne | Head of Business Development and Licensing |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 10, 2026 | 424B3 | Prospectus |
| Sep 10, 2026 | 8-K | Current Report |
| Sep 4, 2026 | SCHEDULE 13G/A | Filing |
| Sep 4, 2026 | SCHEDULE 13G | Filing |
| Aug 31, 2026 | D | Notice of Exempt Offering of Securities |
| Aug 18, 2026 | SCHEDULE 13D | Filing |
| Aug 18, 2026 | SCHEDULE 13G | Filing |
| Aug 14, 2026 | SCHEDULE 13G | Filing |
| Aug 14, 2026 | SCHEDULE 13G | Filing |
| Aug 14, 2026 | SCHEDULE 13G | Filing |